FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials

Targeted Oncology · Published 2026-08-02 · DOI 10.1007/s11523-026-01243-y

Authors (15)

Liqiong Xue, Guopei Zhu, Peiguo Wang, Kunyu Yang, Yan Sun, Weidong Li, Zhendong Li, Cuihong Jiang, Qingqing Cai, Meiyu Fang, Man Hu, Minghua Ge, Wei Zhou, Sichen Li, Ye Guo

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Xue, L., Zhu, G., Wang, P., et al. (2026). FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials. Targeted Oncology. https://doi.org/10.1007/s11523-026-01243-y

Related articles

• Recent highlights and breakthroughs in immunotherapy for head and neck cancers · Current Opinion in Oncology · 2026 · Cites or is cited by this article
• Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis · Targeted Oncology · 2025 · Same journal
• Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer · Targeted Oncology · 2026 · Same journal
• MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies · Targeted Oncology · 2025 · Same journal
• Targeting DNA Damage Repair Pathways Beyond PARP Inhibition · Targeted Oncology · 2025 · Same journal
• Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA · Targeted Oncology · 2026 · Same journal
• Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges · Targeted Oncology · 2026 · Same journal
• Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer · Targeted Oncology · 2026 · Same journal
• Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? · Targeted Oncology · 2026 · Same journal
• Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study) · Targeted Oncology · 2026 · Same journal